Dosimetry to Estimate the Effect of Gelofusine® on the Renal Absorbed Dose of Lutetium 177-DOTA-octreotate. Abstract #1425

Introduction: Lutetium-177 DOTA-octreotate (LuTate), a radiolabelled somatostatin analogue, delivers targeted radiation to neuroendocrine tumours and metastases. Healthy tissues also receive significant irradiation. Charged amino acids are routinely co-infused to block renal proximal tubular LuTate reabsorption. Gelofusine® (a succinylated bovine gelatin molecule), proposed to interact with the megalin/cubulin receptor-mediated transporter system, has been shown to reduce renal uptake of indium-111 octreotide. Routine Gelofusine® administration is limited by risk of allergic reaction.
Aim(s): To utilise personalised dosimetry to assess renal radiation risk from LuTate therapy and the additional effect of Gelofusine® on renal absorbed dose of LuTate.
Materials and methods: Quantitative SPECT images are routinely acquired following the first therapy cycle to estimate accumulated radiation doses delivered to kidneys. Five patients demonstrated a higher than threshold renal radiation dose and received additional renal protection with Gelofusine® for future cycles of LuTate, with repeat dosimetry.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Dr Catherine Lucas

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1263 Pretherapy Identification of Patients at Risk of Receiving a High Renal Dose Undergoing Peptide Receptor Radionuclide Therapy
Introduction: 68GaDOTA TATE imaging of patients with neuroendocrine tumours has shown that tumour sequestration is a major factor leading to a sink effect that decreases activity concentration in healthy tissues, particularly the renal parenchyma.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr Steven Goodman
Keywords: dosimetry, PRRT
#2069 Tumor Absorbed Dosimetry and Response of Radionuclide Therapy in Metastatic Neuroendocrine Tumor
Introduction: Increased tumour lesion absorbed dosimetry (TLAD) from peptide receptor radionuclide therapy (PRRT) is associated with neuroendocrine tumours (NET) response. Responses to PRRT might be impacted by NET grade, site of origin and use of concurrent chemotherapy.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Rahul Ladwa
Authors: Ladwa R, Pattison D, Smith J, Goodman S, ...
#2119 Positron Emission Tomography (PET) Predictors of Tumor Response to Peptide Receptor Radionuclide Therapy (PRRT) in Metastatic Neuroendocrine Tumors (NET)
Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate (68Ga-DOTATATE) PET standardised uptake value (SUV) has shown conflicting results in the prediction of tumour response to radionuclide therapy.
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Rahul Ladwa
Authors: Ladwa R, Pattison D, Smith J, Goodman S, ...
#178 Treatment with 177Lutetium-DOTA-Tyr3-octreotate in Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumors express somatostatin receptors. Treatment with radiolabelled somatostatin analogs has been used for more than 10 years. Useful isotopes are 111Indium, 99Yttrium and 177Lutetium.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Ass Prof Dan Granberg
#2066 Pretherapeutic Predictors of Tumor Absorbed Dosimetry in Radionuclide Therapy for Metastatic Neuroendocrine Tumors
Introduction: Pretherapeutic 68Gallium-DOTA-(0-Tyr3)-octreotate Positron Emission Tomography (68Ga-DOTATATE PET) standardised uptake value (SUV) has shown conflicting results in the prediction of tumour lesion absorbed dosimetry (TLAD).
Conference: 15th Annual ENETS conference (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Rahul Ladwa
Authors: Ladwa R, Pattison D, Smith J, Goodman S, ...